Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENOMIC HEALTH INCGHDX · Entity 153816 | Chief Medical Officer | February 20, 2018 | February 22, 2018 |
| ILLUMINA, INC.ILMN · Entity 3137 | SVP Chief Medical Officer | March 01, 2023 | March 03, 2023 |
| VERACYTE, INC.VCYT · Entity 2018 | Chief Scientific & Med Officer | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENOMIC HEALTH INC
Report date February 20, 2018 · Filed February 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,387 |
Last balance in matching sequence
After 2018-02-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-02-20 · Sale · Disposed 4,642 · Balance 21,687 F1: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F2: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3: Represents weighted average sale price. Actual sale prices ranged from $32.34 to $33.32. F4: Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Row 2 · 2018-02-20 · Sale · Disposed 300 · Balance 21,387 F1: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F2: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F5: Represents weighted average sale price. Actual sale prices ranged from $33.34 to $33.36. F4: Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017.
F2: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
F3: Represents weighted average sale price. Actual sale prices ranged from $32.34 to $33.32.
F4: Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F5: Represents weighted average sale price. Actual sale prices ranged from $33.34 to $33.36.
ILLUMINA, INC.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,786 |
Reported balance
After 2023-03-01 transaction · row 1
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 7,556 · Balance 14,786 F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2023, November 5, 2024, November 5, 2025, and November 5, 2026, subject to awardee's continuing status as a service provider on such dates. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2024-12-29 | Direct | 3,023 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 3,023 · Balance 3,023 F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2025-12-28 | Direct | 4,534 |
Reported balance
After 2023-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-01 · Grant · Acquired 4,534 · Balance 4,534 F3: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 28, 2025. The number of shares issued will range from 0% to 175% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 28, 2025, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2023, November 5, 2024, November 5, 2025, and November 5, 2026, subject to awardee's continuing status as a service provider on such dates.
F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates.
F3: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 28, 2025. The number of shares issued will range from 0% to 175% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 28, 2025, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates.
VERACYTE, INC.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,048 |
Ending reported balance
After 2026-09-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-02 · Tax withholding · Disposed 3,639 · Balance 146,158 F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale. Row 2 · 2026-09-04 · Sale · Disposed 10,405 · Balance 135,753 F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3: Represents weighted average sales price. Sale prices for the transactions range from $42.47 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Row 3 · 2026-09-04 · Sale · Disposed 2,705 · Balance 133,048 F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F4: Represents weighted average sales price. Sale prices for the transactions range from $43.475 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.
F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
F3: Represents weighted average sales price. Sale prices for the transactions range from $42.47 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F4: Represents weighted average sales price. Sale prices for the transactions range from $43.475 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
VARIAN MEDICAL SYSTEMS INC
Report date April 15, 2021 · Filed April 16, 2021
Section 16 reporting ended · disclosed 2021-04-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-15 transaction · row 1
1 source rowRow 1 · 2021-04-15 · Disposition to issuer · Disposed 1,699 · Balance 0 F1: Disposed of pursuant to merger agreement (the "Merger Agreement") between issuer and Siemens Healthineers I GmbH and certain other parties in exchange for a cash payment of $177.50 per share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-04-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-15 · Disposition to issuer · Disposed 1,022 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the earlier of February 15, 2022, or the next Annual Meeting of Stockholders that occurs after the Grant Date, were cancelled in exchange for a cash payment of $177.50 per unvested share of underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to merger agreement (the "Merger Agreement") between issuer and Siemens Healthineers I GmbH and certain other parties in exchange for a cash payment of $177.50 per share of common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of VAR common stock.
F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the earlier of February 15, 2022, or the next Annual Meeting of Stockholders that occurs after the Grant Date, were cancelled in exchange for a cash payment of $177.50 per unvested share of underlying common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2021 Filed Feb 18, 2021 21:44 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006514 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,873 F1 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 111% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 19:06 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | Exercise / conversionRestricted Stock Units · Derivative | 1,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006368 · form4.xml · derivative · entry 3 Febbo Phillip G. · CIK 0001649245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,225 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of February 14, 2021, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of February 14, 2021, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 19:06 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | Exercise / conversionCommon Stock | 1,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006368 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 08:27 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | GrantRestricted Stock Units · Derivative | 1,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005592 · form4.xml · derivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,022 Underlying: Common Stock · 1,022 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of February 15, 2022, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of February 15, 2022, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 23:44 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005282 · form4.xml · derivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,140 Underlying: Common Stock · 4,140 shares Expires 2023-12-31 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 31, 2023. The number of shares issued will range from 0% to 175% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 31,2023, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 31, 2023. The number of shares issued will range from 0% to 175% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 31,2023, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 23:44 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005282 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,523 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2021, November 5, 2022, November 5, 2023, and November 5, 2024, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 22:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 155 | $310.10 | $48,065.50 |
DisclosureSEC source: 0001127602-20-028496 · form4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,143 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 192 | $311.72 | $59,850.24 |
DisclosureSEC source: 0001127602-20-028496 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,298 Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 21:39 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 173 | $300.00 | $51,900.00 |
DisclosureSEC source: 0001127602-20-014142 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| April 05, 2020 Filed Apr 7, 2020 20:32 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 92 | $278.01 | $25,576.92 |
DisclosureSEC source: 0001127602-20-013391 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,663 Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 19:29 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | GrantRestricted Stock Units · Derivative | 1,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006589 · form4.xml · derivative · entry 4 Febbo Phillip G. · CIK 0001649245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,225 Underlying: Common Stock · 1,225 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F3 · derivative.exercise_date: The restricted stock units vest on the earlier of February 14, 2021, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date. F3 · derivative.expiration_date: The restricted stock units vest on the earlier of February 14, 2021, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 19:29 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | Exercise / conversionRestricted Stock Units · Derivative | 474 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006589 · form4.xml · derivative · entry 3 Febbo Phillip G. · CIK 0001649245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F2 · derivative.exercise_date: The restricted stock units vest immediately on grant date of February 14, 2020. F2 · derivative.expiration_date: The restricted stock units vest immediately on grant date of February 14, 2020. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 19:29 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | GrantRestricted Stock Units · Derivative | 474 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-006589 · form4.xml · derivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474 Underlying: Common Stock · 474 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F1 · price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F2 · derivative.exercise_date: The restricted stock units vest immediately on grant date of February 14, 2020. F2 · derivative.expiration_date: The restricted stock units vest immediately on grant date of February 14, 2020. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 19:29 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | Exercise / conversionCommon Stock | 474 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-006589 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 22:49 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 3,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004396 · form4.xml · derivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,746 Underlying: Common Stock · 3,746 shares Expires 2023-01-01 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 22:49 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004396 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,755 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 5, 2021, February 5, 2022, February 5, 2023 and February 5, 2024, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:33 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 155 | $300.00 | $46,500.00 |
DisclosureSEC source: 0001127602-19-033040 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,506 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 83 | $300.87 | $24,972.21 |
DisclosureSEC source: 0001127602-19-032212 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 16:19 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 300 | $33.35 | $10,005.00 |
DisclosureSEC source: 0001209191-18-012405 · doc4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,387 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F5 · price: Represents weighted average sale price. Actual sale prices ranged from $33.34 to $33.36. F4 · balance_after: Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 16:19 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 4,642 | $32.81 | $152,284.99 |
DisclosureSEC source: 0001209191-18-012405 · doc4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,687 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $32.34 to $33.32. F4 · balance_after: Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 17:57 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Tax withholdingCommon Stock | 2,801 | $32.66 | $91,480.66 |
DisclosureSEC source: 0001209191-18-011496 · doc4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,329 F1 · balance_after: Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 19:32 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantEmployee Stock Option (right to buy) Holding · Derivative | 26,060 | $0.00 Strike: $33.21 | $0.00 |
DisclosureSEC source: 0001209191-18-007216 · doc4.xml · derivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,060 Underlying: Common Stock · 26,060 shares Expires 2028-01-31 F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on January 31, 2019, and becomes exercisable as to 1/48th of the shares each full month thereafter. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 19:32 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 11,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007216 · doc4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,130 F1 · shares: Restricted stock units awarded on January 31, 2018 which vest as to 1/3 of the shares on each of February 15, 2019, 2020 and 2021. F2 · balance_after: Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:35 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionEmployee Stock Option (right to buy) Holding · Derivative | 5,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066649 · doc4.xml · derivative · entry 4 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,710 Underlying: Common Stock · 0 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:35 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 334 | $36.82 | $12,297.88 |
DisclosureSEC source: 0001209191-17-066649 · doc4.xml · nonDerivative · entry 3 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,800 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F3 · price: Represents actual sale price. F1 · balance_after: Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:35 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 5,000 | $37.00 | $185,000.00 |
DisclosureSEC source: 0001209191-17-066649 · doc4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,134 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F3 · price: Represents actual sale price. F1 · balance_after: Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:35 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 5,000 | $27.00 | $135,000.00 |
DisclosureSEC source: 0001209191-17-066649 · doc4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 16:20 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 330 | $33.57 | $11,078.10 |
DisclosureSEC source: 0001209191-17-045945 · doc4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,800 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F5 · price: Represents actual sale price. F4 · balance_after: Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 16:20 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 2,844 | $33.57 | $95,460.00 |
DisclosureSEC source: 0001209191-17-045945 · doc4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,130 F1 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $33.31 to $33.80. F3 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · balance_after: Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 18:44 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 1,226 | $30.63 | $37,551.03 |
DisclosureSEC source: 0001209191-17-012364 · doc4.xml · nonDerivative · entry 3 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,644 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 22, 2016. F4 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F5 · price: Represents weighted average sale price. Actual sale prices ranged from $30.36 to $31.02. F1 · balance_after: Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 18:44 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 1,269 | $29.56 | $37,513.29 |
DisclosureSEC source: 0001209191-17-012364 · doc4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,870 F2 · security: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 22, 2016. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $29.25 to $29.95. F4 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F1 · balance_after: Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 18:44 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Tax withholdingCommon Stock | 1,910 | $31.12 | $59,439.20 |
DisclosureSEC source: 0001209191-17-012364 · doc4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,139 F1 · balance_after: Includes an aggregate of 17,800 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 20:08 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantEmployee Stock Option (right to buy) Holding · Derivative | 26,320 | $0.00 Strike: $27.48 | $0.00 |
DisclosureSEC source: 0001209191-17-007330 · doc4.xml · derivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,320 Underlying: Common Stock · 26,320 shares Expires 2027-01-31 F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on January 31, 2018, and becomes exercisable as to 1/48th of the shares each full month thereafter. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 20:08 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 11,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007330 · doc4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,049 F1 · shares: Restricted stock units awarded on January 31, 2017 which vest as to 1/3 of the shares on each of February 15, 2018, 2019 and 2020. F2 · balance_after: Includes an aggregate of 11,114 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 15, 2016 Filed Dec 20, 2016 17:14 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Tax withholdingCommon Stock | 1,066 | $27.00 | $28,782.00 |
DisclosureSEC source: 0001209191-16-156140 · doc4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,241 F1 · balance_after: Includes an aggregate of 11,114 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| August 15, 2015 Filed Dec 20, 2016 17:14 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Tax withholdingCommon Stock | 1,065 | $24.85 | $26,465.25 |
DisclosureSEC source: 0001209191-16-156140 · doc4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,307 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.